Vertex Pharmaceuticals Inc.'s fourth quarter earnings boasted few surprises – the company had already given investors a taste at the J.P. Morgan Healthcare Conference earlier this month – but that didn't stop the Wednesday evening earnings call from running well over an hour as analysts persisted in teasing out management predictions for uptake of cystic fibrosis (CF) drug Orkambi.